{"id":"W4376613634","doi":"10.1016/j.esmoop.2023.101463","title":"124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; PharmaMar; Eisai; Clovis Oncology; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre; Seagen; Relay Therapeutics; Gilead Sciences; Veracyte; Pfizer; Oncolytics Biotech","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Internal medicine; Oncology; Clinical trial; Cancer; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001265819,0.0004258882,0.001536834,0.0003307606,0.00008948881,0.00002085219,0.0004590514,0.0002428913,0.000600427],"category_scores_gemma":[0.0006973567,0.0003897076,0.000172035,0.001139876,0.00078103,0.0004424229,0.0003815788,0.0004968048,0.000005800787],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002683487,"about_ca_system_score_gemma":0.001168232,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02817222,"about_ca_topic_score_gemma":0.004991609,"domain_scores_codex":[0.9963028,0.0004822704,0.001329884,0.0006946429,0.0006680019,0.0005224072],"domain_scores_gemma":[0.9967301,0.0007773441,0.001040402,0.0005581248,0.0005935574,0.000300438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5962059,0.002647765,0.02938593,0.0007472857,0.002556097,0.0002100105,0.02391911,0.0001751219,0.01233427,0.0003860713,0.006146924,0.3252855],"study_design_scores_gemma":[0.168662,0.003455836,0.740895,0.002705507,0.00031656,0.00004522879,0.006877657,0.00007394297,0.07218148,0.002046639,0.002032208,0.0007078921],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983707,0.0002906602,0.00002506152,0.003321425,0.0004268597,0.004296499,0.004393747,0.00005585179,0.003482973],"genre_scores_gemma":[0.996002,0.0007259973,0.001040578,0.0001538515,0.000265596,0.0003081418,0.0001845697,0.00007381825,0.001245458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7115091,"threshold_uncertainty_score":0.9998555,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04569858955533936,"score_gpt":0.339689188929266,"score_spread":0.2939905993739267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}